Volume 19 Issue 8
Aug.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(8): 1314-1317
JIN De-wei, TAO Min, MA Xiao-yan, WANG Yi, SHENG Li-li, LIU Na. Study on risk factors of N-terminal pro-brain natriuretic peptide abnormalities in non-dialysis patients with chronic kidney disease[J]. Chinese Journal of General Practice, 2021, 19(8): 1314-1317. doi: 10.16766/j.cnki.issn.1674-4152.002049
Citation: JIN De-wei, TAO Min, MA Xiao-yan, WANG Yi, SHENG Li-li, LIU Na. Study on risk factors of N-terminal pro-brain natriuretic peptide abnormalities in non-dialysis patients with chronic kidney disease[J]. Chinese Journal of General Practice, 2021, 19(8): 1314-1317. doi: 10.16766/j.cnki.issn.1674-4152.002049
shu

Study on risk factors of N-terminal pro-brain natriuretic peptide abnormalities in non-dialysis patients with chronic kidney disease

doi: 10.16766/j.cnki.issn.1674-4152.002049

  • Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200092, China

Funds:

 81670690

 81470991

 81200492

 20ZR1445800

 PWZxk2017-05

  • Received Date: 2021-02-08
    Available Online: 2022-02-16
    Abstract
  •   Objective   To investigate the risk factors of N-terminal pro-brain natriuretic peptide (NT-proBNP) abnormalities in non-dialysis patients with chronic kidney disease (CKD).   Methods   Non-dialysis patients hospitalized in the Department of Nephrology from January 1, 2018 to December 31, 2019 at the Shanghai East Hospital were enrolled. According to the level of NT-proBNP, patients were divided into NT-proBNP normal group (Ⅰ: NT-proBNP < 125 ng/L) and NT-proBNP abnormal group (Ⅱ: NT-proBNP≥125 ng/L). There were 129 patients in group Ⅰ and 130 patients in group Ⅱ. Multivariate Logistic regression and ROC curve were used to analyze the influencing factors of patients' NT-proBNP abnormalities.   Results   Logistic regression showed that age (P=0.008) was an independent risk factor for NT-proBNP abnormality, and hemoglobin (P=0.014) and eGFR (P < 0.001) were protective factors for patients with NT-proBNP abnormality. ROC analysis showed that when the patient's age was>75.5 years (AUC=0.658, P < 0.001), hemoglobin < 124.5 g/L (AUC=0.769, P < 0.001), eGFR < 47.5 [mL/(min·1.73 m2)] (AUC=0.810, P < 0.001), the risk of NT-proBNP increase will increase significantly.   Conclusion   Age is an independent risk factor for the increase of NT-proBNP, while hemoglobin and eGFR are protective factors.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    ROMAGNANI P, REMUZZI G, GLASSOCK R, et al. Chronic kidney disease[J]. Nat Rev Dis Primers, 2017, 3: 17088. doi: 10.1038/nrdp.2017.88
    [2]
    SONG Y, LOBENE A J, WANG Y, et al. The dash diet and cardiometabolic health and chronic kidney disease: A narrative review of the evidence in east asian countries[J]. Nutrients, 2021, 13(3): 984. doi: 10.3390/nu13030984
    [3]
    陈建峰, 李莹. 上海市浦东城乡老年人估算肾小球滤过率及危险因素分析[J]. 中华全科医学, 2017, 15(5): 823-826. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201705030.htm
    [4]
    GREGG L P, HEDAYATI S S. Management of traditional cardiovascular risk factors in ckd: What are the data?[J]. Am J Kidney Dis, 2018, 72(5): 728-744. doi: 10.1053/j.ajkd.2017.12.007
    [5]
    SUN B, MENG M, WEI J, et al. Long noncoding RNA PVT1 contributes to vascular endothelial cell proliferation via inhibition of miR-190a-5p in diagnostic biomarker evaluation of chronic heart failure[J]. Exp Ther Med, 2020, 19(5): 3348-3354.
    [6]
    刘俊生, 刘莉, 杨丽娟, 等. 血清iPTH、血浆BNP、NT-proBNP水平在CKD 5期患者心功能评价中的应用价值分析[J]. 中华全科医学, 2018, 16(9): 1427-1430. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201809006.htm
    [7]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 10(46): 760-789. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201904009.htm
    [8]
    UNGER T, BORGHI C, CHARCHAR F, et al. 2020 international society of hypertension global hypertension practice guidelines[J]. Hypertension, 2020, 75(6): 1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
    [9]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201804009.htm
    [10]
    LEI L, HE Y, GUO Z, et al. A simple nomogram to predict contrast-induced acute kidney injury in patients with congestive heart failure undergoing coronary angiography[J]. Cardiol Res Pract, 2021. DOI: 10.1155/2021/9614953.
    [11]
    RANGASWAMI J, BHALLA V, BLAIR J E A, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association[J]. Circulation, 2019, 139(16): e840-e878. http://www.ncbi.nlm.nih.gov/pubmed/30852913
    [12]
    HOUSE A A, WANNER C, SARNAK M J, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2019, 95(6): 1304-1317. doi: 10.1016/j.kint.2019.02.022
    [13]
    TSUJIMOTO T, KAJIO H. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease[J]. Eur J Prev Cardiol, 2018, 25(12): 1268-1277. doi: 10.1177/2047487318780035
    [14]
    郝黎明, 李莹, 陈建峰, 等. 托伐普坦对左室射血分数降低心衰患者预后的影响[J]. 中国临床医学, 2018, 25(6): 872-878. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201806003.htm
    [15]
    TANAKA A, HIRAMATSU E, WATANABE Y, et al. Efficacy of long-term treatment with tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure[J]. Ther Apher Dial, 2019, 23(4): 319-327. doi: 10.1111/1744-9987.12789
    [16]
    CHANG D R, YEH H C, TING I W, et al. The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality[J]. Sci Rep, 2021, 11(1): 7851. doi: 10.1038/s41598-021-86541-3
    [17]
    HE J, SHLIPAK M, ANDERSON A, et al. Risk factors for heart failure in patients with chronic kidney disease: The cric (chronic renal insufficiency cohort) study[J]. J Am Heart Assoc, 2017, 6(5): e005336. http://www.onacademic.com/detail/journal_1000039907823510_3eb9.html
    [18]
    LAWSON C A, TESTANI J M, MAMAS M, et al. Chronic kidney disease, worsening renal function and outcomes in a heart failure community setting: A UK national study[J]. Int J Cardiol, 2018, 267: 120-127. doi: 10.1016/j.ijcard.2018.04.090
    [19]
    KIM C J, CHOI I J, PARK H J, et al. Impact of cardiorenal anemia syndrome on short- and long-term clinical outcomes in patients hospitalized with heart failure[J]. Cardiorenal Med, 2016, 6(4): 269-278. doi: 10.1159/000443339
    [20]
    PORTOLÉS J, MARTÍN L, BROSETA J J, et al. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents[J]. Front Med (Lausanne), 2021, 8: 642296. http://www.researchgate.net/publication/350404338_Anemia_in_Chronic_Kidney_Disease_From_Pathophysiology_and_Current_Treatments_to_Future_Agents
    [21]
    EISENGA M F, EMANS M E, VAN DER PUTTEN K, et al. Epoetin beta and c-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease[J]. J Am Heart Assoc, 2019, 8(16): e011130. http://www.researchgate.net/publication/335273832_Epoetin_Beta_and_C-Terminal_Fibroblast_Growth_Factor_23_in_Patients_With_Chronic_Heart_Failure_and_Chronic_Kidney_Disease
    [22]
    MELAMED M L, RAPHAEL K L. Metabolic acidosis in ckd: A review of recent findings[J]. Kidney Med, 2021, 3(2): 267-277. doi: 10.1016/j.xkme.2020.12.006
    [23]
    SELVARAJ S, SHAH S J, OMMERBORN M J, et al. Pulmonary hypertension is associated with a higher risk of heart failure hospitalization and mortality in patients with chronic kidney disease: The jackson heart study[J]. Circ Heart Fail, 2017, 10(6): e003940. http://www.ncbi.nlm.nih.gov/pubmed/28611127
    [24]
    BANSAL N, ZELNICK L, GO A, et al. Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: The cric (chronic renal insufficiency cohort) study[J]. J Am Heart Assoc, 2019, 8(21): e012336. http://www.ncbi.nlm.nih.gov/pubmed/31645163
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (243) PDF downloads(12) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return